Dual Drug Loaded Lipid Nanocarrier Formulations for Topical Ocular Applications

References

• Ung L, Bispo PJM, Shanbhag SS, Gilmore MS, Chodosh J. The persistent dilemma of microbial keratitis: global burden, diagnosis, and antimicrobial resistance. Surv Ophthalmol. 2019;64(3):255–271. doi:10.1016/j.survophthal.2018.12.003
   PubMed Web of Science ®Google Scholar
• Collier SA, Gronostaj MP, MacGurn AK, et al. Estimated burden of keratitis—United States, 2010. MMWR Morb Mortal Wkly Rep. 2014;63(45):1027.
   PubMed Web of Science ®Google Scholar
• Ahn M, Yoon KC, Ryu SK, Cho NC, You IC. Clinical aspects and prognosis of mixed microbial (bacterial and fungal) keratitis. Cornea. 2011;30(4):409–413. doi:10.1097/ICO.0b013e3181f23704
   PubMed Web of Science ®Google Scholar
• Fliney GD, Pecen PE, Cathcart JN, Palestine AG. Trends in treatment strategies for suspected bacterial endophthalmitis. Graefes Arch Clin Exp Ophthalmol. 2018;256(4):833–838. doi:10.1007/s00417-018-3910-3
   PubMed Web of Science ®Google Scholar
• Basak SK, Basak S, Mohanta A, Bhowmick A. Epidemiological and microbiological diagnosis of suppurative keratitis in Gangetic West Bengal, Eastern India. Indian J Ophthalmol. 2005;53(1):17–22. doi:10.4103/0301-4738.15280
   PubMedGoogle Scholar
• Gopinathan U, Sharma S, Garg P, Rao GN. Review of epidemiological features, microbiological diagnosis and treatment outcome of microbial keratitis: experience of over a decade. Indian J Ophthalmol. 2009;57(4):273–279. doi:10.4103/0301-4738.53051
   PubMed Web of Science ®Google Scholar
• Leck AK, Thomas PA, Hagan M, et al. Aetiology of suppurative corneal ulcers in Ghana and south India, and epidemiology of fungal keratitis. BJO. 2002;86(11):1211–1215. doi:10.1136/bjo.86.11.1211
   Web of Science ®Google Scholar
• Ho JW, Fernandez MM, Rebong RA, Carlson AN, Kim T, Afshari NA. Microbiological profiles of fungal keratitis: a 10-year study at a tertiary referral center. J OphthalInflamm Infect. 2016;6(1):5. doi:10.1186/s12348-016-0071-6
   Google Scholar
• Patil A, Lakhani P, Taskar P, et al. Formulation development, optimization, and in vitro–in vivo characterization of natamycin-loaded pegylated nano-lipid carriers for ocular applications. J Pharm Sci. 2018;107(8):2160–2171. doi:10.1016/j.xphs.2018.04.014
   PubMed Web of Science ®Google Scholar
• Patil A, Lakhani P, Taskar P, Avula B, Majumdar S. Carboxyvinyl polymer and guar-borate gelling system containing natamycin loaded pegylated nanolipid carriers exhibit improved ocular pharmacokinetic parameters. J Ocul Pharmacol Ther. 2020;36(6):410–420. doi:10.1089/jop.2019.0140
   PubMed Web of Science ®Google Scholar
• Miller D. Update on the epidemiology and antibiotic resistance of ocular infections. Middle East Afr J Ophthalmol. 2017;24(1):30–42. doi:10.4103/meajo.MEAJO_276_16
   PubMed Web of Science ®Google Scholar
• Patel A, Cholkar K, Agrahari V, Mitra AK. Ocular drug delivery systems: an overview. World J Pharmacol. 2013;2(2):47–64. doi:10.5497/wjp.v2.i2.47
   PubMedGoogle Scholar
• Balguri SP, Adelli GR, Janga KY, Bhagav P, Majumdar S. Ocular disposition of ciprofloxacin from topical, PEGylated nanostructured lipid carriers: effect of molecular weight and density of poly (ethylene) glycol. Int J Pharm. 2017;529(1):32–43. doi:10.1016/j.ijpharm.2017.06.042
   PubMed Web of Science ®Google Scholar
• Fong CF, Tseng CH, Hu FR, Wang IJ, Chen WL, Hou YC. Clinical characteristics of microbial keratitis in a university hospital in Taiwan. Am J Ophthalmol. 2004;137(2):329–336. doi:10.1016/j.ajo.2003.09.001
   PubMed Web of Science ®Google Scholar
• Shah A, Sachdev A, Coggon D, Hossain P. Geographic variations in microbial keratitis: an analysis of the peer-reviewed literature. Br J Ophthalmol. 2011;95(6):762–767. doi:10.1136/bjo.2009.169607
   PubMed Web of Science ®Google Scholar
• Youssef AAA, Cai C, Dudhipala N, Majumdar S. Design of topical ocular ciprofloxacin nanoemulsion for the management of bacterial keratitis. Pharmaceuticals. 2021;14(3):210. doi:10.3390/ph14030210
   Web of Science ®Google Scholar
• Youssef A, Dudhipala N, Majumdar S. Ciprofloxacin loaded nanostructured lipid carriers incorporated into in-situ gels to improve management of bacterial endophthalmitis. Pharmaceutics. 2020;12(6):572. doi:10.3390/pharmaceutics12060572
   PubMed Web of Science ®Google Scholar
• Friedlaender MH. A review of the causes and treatment of bacterial and allergic conjunctivitis. Clin Ther. 1995;17(5):800–810. doi:10.1016/0149-2918(95)80058-1
   PubMed Web of Science ®Google Scholar
• Stergiopoulou T, Meletiadis J, Sein T, et al. Comparative pharmacodynamic interaction analysis between ciprofloxacin, moxifloxacin and levofloxacin and antifungal agents against Candida albicans and Aspergillus fumigatus. J Antimicrob Chemother. 2009;63(2):343–348. doi:10.1093/jac/dkn473
   PubMed Web of Science ®Google Scholar
• Janga KY, Tatke A, Dudhipala N, et al. Gellan gum based sol-to-gel transforming system of natamycin transfersomes improves topical ocular delivery. J Pharmacol Exp Ther. 2019;370(3):814–822. doi:10.1124/jpet.119.256446
   PubMed Web of Science ®Google Scholar
• Janga KY, Tatke A, Balguri SP, et al. Ion-sensitive in situ hydrogels of natamycin bilosomes for enhanced and prolonged ocular pharmacotherapy: in vitro permeability, cytotoxicity and in vivo evaluation. Artif Cells Nanomed Biotechnol. 2018;46(sup1):1039–1050. doi:10.1080/21691401.2018.1443117
   PubMed Web of Science ®Google Scholar
• Tatke A, Dudhipala N, Janga KY, et al. In situ gel of triamcinolone acetonide-loaded solid lipid nanoparticles for improved topical ocular delivery: tear kinetics and ocular disposition studies. Nanomaterials. 2019;9(1):33. doi:10.3390/nano9010033
   Web of Science ®Google Scholar
• Ali M, Byrne ME. Challenges and solutions in topical ocular drug-delivery systems. Expert Rev Clin Pharmacol. 2008;1(1):145–161. doi:10.1586/17512433.1.1.145
   PubMed Web of Science ®Google Scholar
• Dudhipala N, Ali Youssef AA, Banala N. Colloidal lipid nanodispersion enriched hydrogel of antifungal agent for management of fungal infections: comparative in-vitro, ex-vivo and in-vivo evaluation for oral and topical application. Chem Phys Lipids. 2020;233:104981. doi:10.1016/j.chemphyslip.2020.104981
   PubMed Web of Science ®Google Scholar
• Farid RM, El-Salamouni NS, El-Kamel AH, El-Gamal SS. Chapter 16 - Lipid-based nanocarriers for ocular drug delivery. In: Andronescu E, Grumezescu AM editors. Nanostructures for Drug Delivery. Micro and Nano Technologies Elsevier; 2017:495–522. doi:10.1016/B978-0-323-46143-6.00016-6.
   Google Scholar
• Dudhipala N, Ay AA. Amelioration of ketoconazole in lipid nanoparticles for enhanced antifungal activity and bioavailability through oral administration for management of fungal infections. Chem Phys Lipids. 2020;232:104953. doi:10.1016/j.chemphyslip.2020.104953
   PubMed Web of Science ®Google Scholar
• Müller RH, Radtke M, Wissing SA. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv Drug Deliv Rev. 2002;54:S131–S155. doi:10.1016/S0169-409X(02)00118-7
   PubMed Web of Science ®Google Scholar
• Agrahari V, Mandal A, Agrahari V, et al. A comprehensive insight on ocular pharmacokinetics. Drug Deliv and Transl Res. 2016;6(6):735–754. doi:10.1007/s13346-016-0339-2
   PubMed Web of Science ®Google Scholar
• Ghadiri M, Fatemi S, Vatanara A, et al. Loading hydrophilic drug in solid lipid media as nanoparticles: statistical modeling of entrapment efficiency and particle size. Int J Pharm. 2012;424(1–2):128–137. doi:10.1016/j.ijpharm.2011.12.037
   PubMed Web of Science ®Google Scholar
• Cirri M, Maestrini L, Maestrelli F, et al. Design, characterization and in vivo evaluation of nanostructured lipid carriers (NLC) as a new drug delivery system for hydrochlorothiazide oral administration in pediatric therapy. Drug Deliv. 2018;25(1):1910–1921. doi:10.1080/10717544.2018.1529209
   PubMed Web of Science ®Google Scholar
• Zur Mühlen A, Schwarz C, Mehnert W. Solid lipid nanoparticles (SLN) for controlled drug delivery – drug release and release mechanism. Eur J Pharm Biopharm. 1998;45(2):149–155. doi:10.1016/S0939-6411(97)00150-1
   PubMed Web of Science ®Google Scholar
• Dudhipala N, Janga KY, Gorre T. Comparative study of nisoldipine-loaded nanostructured lipid carriers and solid lipid nanoparticles for oral delivery: preparation, characterization, permeation and pharmacokinetic evaluation. Artif Cells, Nanomed Biotechnol. 2018;46(sup2):616–625. doi:10.1080/21691401.2018.1465068
   PubMed Web of Science ®Google Scholar
• Wu Y, Liu Y, Li X, et al. Research progress of in-situ gelling ophthalmic drug delivery system. AJPS. 2019;14(1):1–15. doi:10.1016/j.ajps.2018.04.008
   Web of Science ®Google Scholar
• Rozier A, Mazuel C, Grove J, Plazonnet B. Gelrite®: a novel, ion-activated, in-situ gelling polymer for ophthalmic vehicles. Effect on bioavailability of timolol. Int J Pharm. 1989;57(2):163–168. doi:10.1016/0378-5173(89)90305-0
   Web of Science ®Google Scholar
• Balasubramaniam J, Pandit JK. Ion-activated in situ gelling systems for sustained ophthalmic delivery of ciprofloxacin hydrochloride. Drug Deliv. 2003;10(3):185–191. doi:10.1080/713840402
   PubMed Web of Science ®Google Scholar
• Balasubramaniam J, Kant S, Pandit JK. In vitro and in vivo evaluation of the gelrite gellan gum-based ocular delivery system for indomethacin. Acta Pharm. 2003;53(4):251–261.
   PubMedGoogle Scholar
• Tomlinson A, Khanal S. Assessment of tear film dynamics: quantification approach. Ocul Surf. 2005;3(2):81–95. doi:10.1016/S1542-0124(12)70157-X
   PubMed Web of Science ®Google Scholar
• Morris ER, Nishinari K, Rinaudo M. Gelation of gellan – a review. Food Hydrocoll. 2012;28(2):373–411. doi:10.1016/j.foodhyd.2012.01.004
   Web of Science ®Google Scholar
• Uddin M, Mamun AA, Kabir M, et al. Quality control tests for ophthalmic pharmaceuticals: pharmacopoeial standards and specifications. JAMPS. 2017;14(2):1–17. doi:10.9734/JAMPS/2017/33924
   Google Scholar
• Das S, Ng WK, Tan RBH. Are nanostructured lipid carriers (NLCs) better than solid lipid nanoparticles (SLNs): development, characterizations and comparative evaluations of clotrimazole-loaded SLNs and NLCs? Eur J Pharm Sci. 2012;47(1):139–151. doi:10.1016/j.ejps.2012.05.010
   PubMed Web of Science ®Google Scholar
• Dudhipala N, Gorre T. Neuroprotective effect of ropinirole lipid nanoparticles enriched hydrogel for parkinson’s disease: in vitro, ex vivo, pharmacokinetic and pharmacodynamic evaluation. Pharmaceutics. 2020;12(5):448. doi:10.3390/pharmaceutics12050448
   PubMed Web of Science ®Google Scholar
• Siepmann J, Peppas NA. Modeling of drug release from delivery systems based on hydroxypropyl methylcellulose (HPMC). Adv Drug Deliv Rev. 2001;64:19.
   Google Scholar
• Kowalski RP, Dhaliwal DK, Karenchak LM, et al. Gatifloxacin and moxifloxacin: an in vitro susceptibility comparison to levofloxacin, ciprofloxacin, and ofloxacin using bacterial keratitis isolates. Am J Ophthalmol. 2003;136(3):500–505. doi:10.1016/S0002-9394(03)00294-0
   PubMed Web of Science ®Google Scholar
• Sharma N, Chacko J, Velpandian T, et al. Comparative evaluation of topical versus intrastromal voriconazole as an adjunct to natamycin in recalcitrant fungal keratitis. Ophthalmology. 2013;120(4):677–681. doi:10.1016/j.ophtha.2012.09.023
   PubMed Web of Science ®Google Scholar
• Motukupally S, Nanapur V, Chathoth K, et al. Ocular infections caused by candida species: type of species, in vitro susceptibility and treatment outcome. Indian J Med Microbiol. 2015;33(4):538–546. doi:10.4103/0255-0857.167331
   PubMed Web of Science ®Google Scholar
• Agarwal P, Rupenthal ID. In vitro and ex vivo corneal penetration and absorption models. Drug Deliv and Transl Res. 2016;6(6):634–647. doi:10.1007/s13346-015-0275-6
   PubMed Web of Science ®Google Scholar
• Seyfoddin A, Al-Kassas R. Development of solid lipid nanoparticles and nanostructured lipid carriers for improving ocular delivery of Acyclovir. Drug Dev Ind Pharm. 2013;39(4):508–519. doi:10.3109/03639045.2012.665460
   PubMed Web of Science ®Google Scholar
• Foster KA, Yazdanian M, Audus KL. Microparticulate uptake mechanisms of in-vitro cell culture models of the respiratory epithelium. J Pharm Pharmacol. 2001;53(1):57–66. doi:10.1211/0022357011775190
   PubMed Web of Science ®Google Scholar
• Serra L, Doménech J, Peppas N. Engineering design and molecular dynamics of mucoadhesive drug delivery systems as targeting agents. Eur J Pharm Biopharm. 2009;71(3):519–528. doi:10.1016/j.ejpb.2008.09.022
   PubMed Web of Science ®Google Scholar